Join

Compare · BSX vs EMBC

BSX vs EMBC

Side-by-side comparison of Boston Scientific Corporation (BSX) and Embecta Corp. (EMBC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BSX and EMBC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BSX is the larger of the two at $72.16B, about 359.9x EMBC ($200.5M).
  • Over the past year, BSX is down 51.3% and EMBC is down 66.3% - BSX leads by 15.1 points.
  • BSX has been more active in the news (12 items in the past 4 weeks vs 5 for EMBC).
  • BSX has more recent analyst coverage (25 ratings vs 9 for EMBC).
PerformanceBSX-51.28%EMBC-66.35%
2025-06-09+0.00%2026-06-08
MetricBSXEMBC
Company
Boston Scientific Corporation
Embecta Corp.
Price
$48.73+0.35%
$3.33-1.48%
Market cap
$72.16B
$200.5M
1M return
-13.86%
-7.62%
1Y return
-51.28%
-66.35%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
News (4w)
12
5
Recent ratings
25
9
BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

EMBC

Embecta Corp.

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Latest BSX

Latest EMBC